Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

Develops antibody medicines for oncology, nephrology, immunology, and allergy.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyowa Kirin is a global specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug discovery. The company engages in the research, development, manufacturing, and commercialization of pharmaceuticals and biotechnology products. Focusing on core therapeutic areas such as nephrology, oncology, immunology, and allergy, Kyowa Kirin leverages its advanced antibody technologies to create novel medicines. Guided by its mission of "Commitment to Life," the organization strives to deliver life-changing value to patients, their families, and medical professionals worldwide by developing and marketing innovative prescription drugs that contribute to global health and well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:30
Interim Report
半期報告書-第103期(2025/01/01-2025/12/31)
Japanese 991.7 KB
2025-07-31 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 09:30
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-03-21 06:47
Registration Form
訂正有価証券届出書(参照方式)
Japanese 46.5 KB
2025-03-21 06:41
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB
2025-03-19 07:51
Registration Form
有価証券届出書(参照方式)
Japanese 56.3 KB
2025-03-11 07:31
Annual Report
有価証券報告書-第102期(2024/01/01-2024/12/31)
Japanese 4.0 MB
2025-03-11 07:31
Governance Information
内部統制報告書-第102期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-11 07:31
Registration Form
確認書
Japanese 8.2 KB
2024-11-14 07:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.6 KB
2024-10-31 07:30
Board/Management Information
臨時報告書
Japanese 26.1 KB
2024-10-11 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-09-12 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2024-08-09 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.1 KB
2024-08-01 08:31
Interim Report
半期報告書-第102期(2024/01/01-2024/12/31)
Japanese 916.7 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.